Notes and references
1 For selected reviews, see: (a) F. Kratz, I. A. Muller, C. Ryppa and A.
Warnecke, ChemMedChem, 2008, 3, 20; (b) I. Tranoy-Opalinski, A.
Fernandes, M. Thomas, J. P. Gesson and S. Papot, Anticancer Agents
Med. Chem., 2008, 8, 618.
2 For selected reviews, see: (a) N. Johnsson and K. Johnsson, ACS Chem.
Biol., 2007, 2, 31; (b) J.-L. Reymond, V. S. Fluxa and N. Maillard, Chem.
Commun., 2009, 34.
3 For selected recent examples, see: (a) S. S. Chandran, K. A. Dickson
and R. T. Raines, J. Am. Chem. Soc., 2005, 127, 1652; (b) G. B. Jones,
C. F. Crasto, J. E. Mathews, L. Xie, M. O. Mitchell, A. El-Shafey,
A. V. D’Amico and G. J. Bubley, Bioorg. Med. Chem., 2006, 14, 418;
(c) L. D. Lavis, T.-Y. Chao and R. T. Raines, ChemBioChem, 2006, 7,
1151; (d) L. D. Lavis, T.-Y. Chao and R. T. Raines, ACS Chem. Biol.,
2006, 1, 252; (e) E. Danieli and D. Shabat, Bioorg. Med. Chem., 2007,
15, 7318; (f) M. Waibel, X.-B. Zhang and J. Hasserodt, Synthesis, 2009,
318; (g) X.-B. Zhang, M. Waibel and J. Hasserodt, Chem.–Eur. J., 2010,
16, 792.
4 N.-H. Ho, R. Weissleder and C.-H. Tung, ChemBioChem, 2007, 8, 560.
5 J.-A. Richard, Y. Meyer, V. Jolivel, M. Massonneau, R. Dumeunier, D.
Vaudry, H. Vaudry, P.-Y. Renard and A. Romieu, Bioconjugate Chem.,
2008, 19, 1707.
Fig. 4 Fluorescence emission time-course of pro-fluorescent probes 2–6
(concentration: 3.0 mM) with recombinant PGA (0.12 U, 37 ◦C) in PBS
buffer at 460 nm (lex = 360 nm).
6 X. Chen, M. Sun and H. Ma, Curr. Org. Chem., 2006, 10, 477.
7 J.-A. Richard, M. Massonneau, P.-Y. Renard and A. Romieu, Org.
Lett., 2008, 10, 4175.
8 For selected reviews, see: (a) D. V. McGrath, Mol. Pharmaceutics, 2005,
2, 253; (b) P. Gomes, N. Vale and R. Moreira, Molecules, 2007, 12,
2484.
9 For selected examples about the use of PABA (or its hydroxylated
analogue), see: (a) C. Fossey, A.-H. Vu, A. Vidu, I. Zarafu, D. Laduree,
S. Schmidt, G. Laumond and A.-M. Aubertin, J. Enzyme Inhib. Med.
Chem., 2007, 22, 591; (b) C. Fossey, N.-T. Huynh, A.-H. Vu, A. Vidu,
I. Zarafu, D. Laduree, S. Schmidt, G. Laumond and A.-M. Aubertin,
J. Enzyme Inhib. Med. Chem., 2007, 22, 608; (c) K. A. Ajaj, M. L.
Biniossek and F. Kratz, Bioconjugate Chem., 2009, 20, 390; (d) A.
Fernandes, A. Viterisi, F. Coutrot, S. Potok, D. A. Leigh, V. Aucagne
and S. Papot, Angew. Chem., Int. Ed., 2009, 48, 6443.
10 R. Erez and D. Shabat, Org. Biomol. Chem., 2008, 6, 2669; a similar
study was published by Warnecke et al. but the self-eliminating structure
was activated with a chemical reagent and solubility problems did not
allow evaluation of the disassembly under physiological conditions.
See: A. Warnecke and F. Kratz, J. Org. Chem., 2008, 73, 1546.
11 R. Perry-Feigenbaum, P. S. Baran and D. Shabat, Org. Biomol. Chem.,
2009, 7, 4825.
12 H. Y. Lee, X. Jiang and D. Lee, Org. Lett., 2009, 11, 2065.
13 Unpublished results.
14 Y. Meyer, J. A. Richard, M. Massonneau, P.-Y. Renard and A. Romieu,
Org. Lett., 2008, 10, 1517.
15 A model pro-fluorescent compound composed of phenylacetamide,
Waldmann linker and 7-hydroxycoumarin-4-acetic acid moieties was
firstly synthesised and subjected to PGA hydrolysis. However, a
significant non-specific hydrolysis was observed and evaluated to
30% by RP-HPLC quantification of the released 2-(aminomethyl)-4,5-
dimethoxy-benzeneacetic acid.
In conclusion, self-immolative linkers based on the hemithioam-
inal core disassemble slower than PABA analogues when us-
ing N,N¢-dimethylethylendiamine as a stabilising spacer. Thus,
PABA derivatives will be used for getting fast-response probes
whereas the hemithioaminal spacers will be preferred for the
construction of tunable (bio)functionalised probes. Indeed, these
latter compounds exhibit a conveniently positioned carboxylic
acid group which may be used as an anchoring point for
grafting either: (1) a water-solubilising group such as poly-
sulfonated peptide-based linkers19 especially to counterbalance
the hydrophobicity of the grafted fluorophore, (2) an additional
peptide as part of the substrate for endoproteases, to increase the
enzyme specificity/selectivity or binding or (3) a targeting ligand
suitable for driving the designed pro-fluorescent probe or prodrug
to the targeted tissue and/or proteolytic enzyme. The present
study thus both widens the scope of accessible self-immolative
linkers, and provides additional informations to those recently
published by the groups of Lee, Shabat and Warnecke. This
thus should aid the choice and design of suitable self-immolative
systems useful for the development of optical bioprobes or drug
delivery vehicles suitable, for instance, for cancer imaging and
chemotherapy.
Acknowledgements
16 M. P. Samant, R. White, D. J. Hong, G. Croston, P. M. Conn, J. A.
Janovick and J. Rivier, J. Med. Chem., 2007, 50, 2067.
This work was supported by La Re´gion Haute-Normandie via
the CRUNCh program (CPER 2007-2013), QUIDD and Institut
Universitaire de France (IUF). We thank CNRS and QUIDD
for a PhD grant to Yves Meyer. Recombinant A. faecalis PGA
was gratefully furnished by Pr. L. Fischer, Universita¨t Hohenheim
(Institut fu¨r Lebensmitteltechnologie, Fachgebiet Biotechnologie,
Stuttgart).
17 A. Satyam, Bioorg. Med. Chem. Lett., 2008, 18, 3196.
18 (a) S. Far and O. Melnyk, Tetrahedron Lett., 2004, 45, 7163; (b) M.
Lapeyre, J. Leprince, M. Massonneau, H. Oulyadi, P.-Y. Renard, A.
Romieu, G. Turcatti and H. Vaudry, Chem.–Eur. J., 2006, 12, 3655;
(c) O. P. Varghese, W. Sun, J. Hilborn and D. A. Ossipov, J. Am. Chem.
Soc., 2009, 131, 8781.
19 A. Romieu, D. Brossard, M. Hamon, H. Outaabout, C. Portal and P.-Y.
Renard, Bioconjugate Chem., 2008, 19, 279.
1780 | Org. Biomol. Chem., 2010, 8, 1777–1780
This journal is
The Royal Society of Chemistry 2010
©